New York State Common Retirement Fund grew its position in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 7.4% during the 4th ...

Find insight on AstraZeneca, Celltrion and more in the latest Market Talks covering the Health Care sector.

Learn more about whether AstraZeneca PLC or Intra-Cellular Therapies, Inc. is a better investment based on AAII's A+ Investor ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

AstraZeneca AZN stock has risen 8.6% in the past month, mainly due to mixed fourth-quarter results and a positive update from ...

Allworth Financial LP boosted its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 12.9% in the fourth quarter, ...

In a Phase Ib trial, 71 percent of patients responded to zongertinib and lived a median six months before disease progression or death.

AstraZeneca PLC outperforms 2024 earnings estimates but faces challenges in 2025. Read why AZN patent expiries and mixed ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

Among the newly launched brands, the gastro segment recorded the highest sales at Rs 167 crore from 394 brands. The ...

India's pharmaceutical market is witnessing a surge in new drug launches, particularly in the oncology segment, fueled by a ...